Atlas Trials

Modulation Of The Tumour Microenvironment Using Either Vascular Disrupting Agents or STAT3 Inhibition in Order to Synergise With PD1 Inhibition in Microsatellite Stable, Refractory Colorectal Cancer

Clinical trial NCT03647839 · COMPLETED

Trial details

NCT number
NCT03647839
Sponsor
Australasian Gastro-Intestinal Trials Group
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Colorectal Cancer Metastatic
Start date
2018-09-06
Primary completion
2021-01-29
Enrollment
90

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.